The U.S. Food and Drug Administration announced it will work with manufacturers to remove longstanding boxed (black‑box) warnings from hormone replacement therapies for menopause. FDA officials, including Commissioner Marty Makary, cited accumulating evidence that earlier risks were overstated and said updated labeling could expand safe access for people with menopausal symptoms. Clinical researchers including investigators from the Women’s Health Initiative emphasized the need for clear guidance to avoid confusion among prescribers and patients.